TerrAscend (TSNDF) Depreciation & Amortization (CF) (2021 - 2026)
TerrAscend's (TSNDF) quarterly Depreciation & Amortization (CF) came in at $4.1 million in Q1 2026, up 4.92% year-on-year from $3.9 million in Q1 2025, and up 4.6% on a QoQ basis from $4.0 million in Q4 2025.
TerrAscend (TSNDF) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $4.1 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 4.92% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 17.14% increase from a year earlier, with the FY2025 full-year figure at $15.6 million, up 7.32% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $4.1 million, up from $4.0 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for TSNDF reached as high as $6.6 million in Q2 2022 and fell as low as -$339000.0 in Q4 2023.
- Historically, Depreciation & Amortization (CF) has averaged $4.2 million across 5 years, with a median of $4.1 million in 2026.
- Across the five-year window, Depreciation & Amortization (CF) slumped 106.72% in 2023 and soared 1043.36% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $5.0 million in 2022, then slumped by 106.72% to -$339000.0 in 2023, then surged by 1043.36% to $3.2 million in 2024, then grew by 23.76% to $4.0 million in 2025, then rose by 4.6% to $4.1 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $4.1 million in Q1 2026, $4.0 million in Q4 2025, and $3.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | 4.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.14 Mn |
| Mar 31, 2026 | 4.14 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Jun 30, 2025 | 3.78 Mn |
| Mar 31, 2025 | 3.95 Mn |
| Mar 31, 2025 | 3.95 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | 3.78 Mn |
| Sep 30, 2024 | 3.78 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Mar 31, 2024 | 5.00 Mn |
| Dec 31, 2023 | -339,000.00 |
| Dec 31, 2023 | -339,000.00 |